Guerbet: 1st quarter 2015 revenue
April 23 2015 - 11:08AM
Strong growth in sales
+12.1% at constant exchange rates
VILLEPINTE, France, April 23, 2015 (GLOBE
NEWSWIRE) -- Guerbet (FR0000032526 GBT), a global
specialist in contrast agents and solutions for medical imaging, is
publishing revenue of €112.2M for the 1st quarter of 2015, up by
16.2% compared with 31 March 2014. At constant exchange rates, its
revenue grew by 12.1%.
Consolidated Group revenue (IFRS)
In millions of Euros, at 31 March |
2015 |
2014 |
Change (%) |
Sales in Europe |
78.8 |
72.1 |
9.3% |
Sales in Other
Markets |
33.4 |
24.5 |
36.3% |
Total 1st quarter
revenue |
112.2 |
96.6 |
16.2% |
Growth in every geographic region
The 1st quarter 2015 revenue in Europe totalled
€78.8M, up 7.6% at constant exchange rates, driven mainly by the
revival of activity in Germany. Growth in Europe was 9.3% at
current exchange rates, with a particularly favourable exchange
rate effect in Switzerland.
Sales increased sharply in the Other Markets,
gaining 24.8% at constant exchange rates. This performance is due
to the strong surge in sales of Dotarem® in the USA, the
continued upturn in activity in Brazil and growth in Asia.
All product segments growing again
The revenue generated in the MRI segment
amounted to €47.3M, versus €39.9M in 2014, i.e. 18.3% growth driven
by the USA and Germany. Sales of Xenetix® were responsible
for the development of the X-Ray segment, whose revenue
totalled €48.6M, rising by 3.4%. Sales in the IRT segment
more than doubled with the success of Lipiodol® and
Patent Blue V. Finally, activity in the medical devices
segment gained 10%.
Visibility still limited for the full
year
Despite this very good start to the year,
visibility is still limited by the uncertainties about the
launching of Dotarem® generics in Europe.
In the X-Ray business, growth should be
affected for the next few quarters. The delay in bringing the new
ScanBag® filling line up to its expected production rate
will no longer be offset by the inventories of bags produced in
2014 from which the first quarter benefited.
Ultimately, in this environment of limited
visibility in the next few quarters, the Group is confirming its
projection of sales growth in 2015.
Upcoming events:
- General Meeting of Shareholders: 29 May 2015 at 2.30pm
- Publication of 2nd quarter 2015 revenue: 28 July 2015 after
trading
About Guerbet
Guerbet is a pioneer in the contrast agent
field, with nearly 90 years' experience, and is the only
pharmaceutical group dedicated to medical imaging worldwide. It
offers a comprehensive range of X-Ray, Magnetic Resonance Imaging
(MRI) and Interventional Radiology and Theranostics (IRT) products,
along with a range of injectors and related medical devices to
improve the diagnosis and treatment of patients. To discover new
products and ensure future growth, Guerbet invests heavily in
R&D, spending around 9% of its sales each year. Guerbet (GBT)
is listed on NYSE Euronext Paris (Segment B - Mid Caps) and
generated revenue of €409 million in 2014. It had a total workforce
of 1,461 employees at 31 December 2014.
For more information about Guerbet,
please go to www.guerbet.com
Contacts
Jean-François Le
Martret Chief Financial Officer 01 45 91 50 00
|
Christophe de
Lylle/Benjamin Lehari 01 56 88 11 11
cdelylle@actifin.fr/blehari@actifin.fr Press Jennifer
Jullia 01 56 88 11 19 jjullia@actifin.fr |
Press release http://hugin.info/159769/R/1914056/683867.pdf
HUG#1914056
Guerbet (EU:GBT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Guerbet (EU:GBT)
Historical Stock Chart
From Oct 2023 to Oct 2024